目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T1739 | CXCR | ||
WZ811 是可口服的高竞争性CXCR4拮抗剂,抑制细胞中 CXCR4/SDF-1 介导的 cAMP 水平调节和 SDF-1 诱导的基质胶侵入,EC50为 1.2 和 5.2 nM。 | |||
T4033 | CXCR | ||
MSX-130 是一种CXCR4拮抗剂,可抑制肿瘤转移。 | |||
T9721 | CXCR | ||
ML339 是有效的CXCR6选择性拮抗剂,IC50为 140 nM。ML339 对 CXCR5,CXCR4,CCR6 和 Apelin 受体 (APJ) 无拮抗作用,IC50>79 μM。ML339 在前列腺癌研究领域有研究的价值。 | |||
T4032 | CXCR | ||
MSX-127 是一种CXCR4拮抗剂,可抑制肿瘤转移。 | |||
T2477 | CXCR Autophagy | ||
UNBS5162 (UNBS-5162) 是一种新型萘酰亚胺,可降低实验性前列腺癌中 CXCL 趋化因子的表达。它是一种广谱趋化因子配体CXCL 拮抗剂,具有抗肿瘤活性。 | |||
TQ0174 | CXCR | ||
Mavorixafor (AMD-070) 是一种有效的特异性 CXCR4 拮抗剂,对 CXCR4 125I-SDF 结合的 IC50 值为 13 nM。 Mavorixafor 在 MT-4 细胞 (IC50 = 1 nM) 和 PBMC (IC50 = 9 nM) 中抑制 T-tropic HIV-1 (NL4.3 株) 的复制。 | |||
T5193 | CXCR | ||
Danirixin (GSK1325756) 是一种选择性可逆的CXCR2拮抗剂,抑制 CXCL8 的IC50值为 12.5 nM。 | |||
T3992 | CXCR | ||
MSX-122 是可口服的CXCR4部分拮抗剂,具有抗炎和抗转移活性,可抑制CXCR4/CXCL12相互作用,IC50值约为 10 nM。 | |||
T17208 | CXCR | ||
USL311 是选择性 CXCR4拮抗剂,可防止基质细胞衍生因子 1(SDF-1 或 CXCL12)与 CXCR4 结合。它抑制 CXCR4 活化并减少表达 CXCR4 的肿瘤细胞的增殖和迁移,具有抗肿瘤活性。 | |||
T4163 | CXCR | ||
Reparixin (Repertaxin) 是两种 CXCL8 受体 CXCR1/2 的强效抑制剂,它对 CXCR2 介导的细胞迁移具有微弱的抑制作用 ,IC50为 100 nM。它强烈阻断 CXCR1 介导的趋化性,IC50为 1 nM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-02612 | CXCR3 Protein, Mouse, Recombinant (His & KSI) | Mouse | E. coli | ||
Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of mesangial cells through a heterotrimeric G-protein signaling pathway. Probably promotes cell chemotaxis response. Binds to CCL21.
|
|||||
TMPH-01162 | CXCR3 Protein, Human, Recombinant (GST & His) | Human | E. coli | ||
CXCR3 Protein, Human, Recombinant (GST & His) is expressed in E. coli.
|
|||||
TMPY-06553 | CXCR4 Protein, Human, Recombinant | Human | HEK293 | ||
CXCR4 Protein, Human, Recombinant is expressed in HEK293. The predicted molecular weight is 39.75 kDa. Accession number: P61073-1
|
|||||
TMPJ-01037 | CXCR4 Protein, Human, Recombinant (hFc) | Human | Human Cells | ||
C-X-C chemokine receptor type 4 (CXCR4) is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. CXCR4 stands out for its pleiotropic roles in both physiological and pathological conditions and it represents a crucial target in drug development. CXCL12 is the principal CXCR4 specific ligand and that the pro-inflammatory chemokine macrophage migration inhibitory factor (MIF) is also able to bind and activate CXCR4.
|
|||||
TMPJ-00760 | CXCL7 Protein, Human, Recombinant | Human | E. coli | ||
Human Chemokine (C-X-C motif) Ligand 7 (CXCL7), also known as neutrophil activating peptide 2 (NAP-2), is a member of the CXC chemokines containing an ELR domain (Glu-Leu-Arg tripeptide motif). Similar to other ELR domain containing CXC chemokines, such as IL-8 and the GRO proteins, CXCL7 binds CXCR2, chemoattracts and activates neutrophils. CXCL7, Connective Tissue Activating Protein III (CTAPIII) and βthrombogulin (βTG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. Although CTAPIII, βTG, and PBP represent amino-terminal extended variants of NAP2 and possess the same CXC chemokine domains, these proteins do not exhibit CXCL7/NAP2 activity. CXCL7 induces cell migration through the G-protein-linked receptor CXCR-2.
|